Answers are grounded in this paper and cite their sources.
studies demonstrated that PEG-MSN@ATO enhanced the antitumor efficacy by inducing apoptosis and ROS production, inhibiting tumor cell proliferation and metastasis, and activating antitumor immunity within the TME. PEG-MSN@ATO also reduced the system toxicity of ATO by controlling the pH-trigger release in the tumor site. These results indicate that the PEG-MSN@ATO represents a promising drug delivery platform for reducing toxicity and enhancing the therapeutic efficacy of ATO against LC.
No takes yet. Share an insight, caveat, or question.
Jiang et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: